Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FURI open-label ibrexafungerp study in refractory, resistant, or intolerant fungal disease
2017-000381-29Phase 3Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- May 2017
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ibrexafungerp in invasive mycoses, mycoses, vulvovaginal candidiasis (VVC) and 3 more, sponsored by SCYNEXIS, Inc. Primary endpoint: Global Response at primary timepoint by Data Review Committee. Started May 2017; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
invasive mycosesmycosesvulvovaginal candidiasis (VVC)chronic mucocutaneous candidiasis (CMC)chronic pulmonary aspergillosis (CPA)
Beyond the preview
Go deeper on 2017-000381-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000381-29.